Sumitomo Pharma disclosed the variance between its consolidated earnings forecast and actual results for the second quarter of the fiscal year ending March 2027, and also revised its full-year consolidated earnings forecast. The release indicates changes to the outlook for the interim period.
Sumitomo Pharma disclosed the variance between its consolidated earnings forecast and actual results for the second quarter.
It also explicitly stated that its full-year consolidated earnings forecast had been revised.